A Trustworthy Double Twist On 3-Methyladenine

904 men underwent a radical orchidectomy; (310, 247 and 347 in the 2003, 2006 and 2010 cohorts). Data was missing in 19(2.1%). 413(45.7%) were counselled regarding the insertion of a prosthesis. 228(25.2%) underwent concurrent orchidectomy and prosthesis insertion (55% of those counselled). 8(0.9%) underwent prosthesis insertion at a later date. There was a significant difference in age between those receiving a prosthesis and those who did not, 32 vs. 35 years (p http://www.selleckchem.com/products/PD-0325901.html of stay for concurrent prosthetic vs. non-prosthetic patients was 2 vs. 3 days (p = 0.3), 30 day re-admission rate was 2.6% vs. 4.4% (p = 0.54) and the 30 day return to theatre rate was 1.3% vs. 1.6%. (p = 1.0). One concurrent prosthesis required change to a smaller size, no additional patients required removal. http://www.selleckchem.com/products/3-methyladenine.html Over half of men offered a prosthesis take up the option. Concurrent prosthesis insertion is not associated with an increased risk of complications and can be offered routinely and safely to men undergoing radical orchidectomy. Wednesday 19 June 2013 Poster Session 7 13:30�C15:30?Charter 2 FEMALE UROLOGY Chairs: Mr Arun Sahai & Mr Simon Fulford Posters P81�CP92 AK Nambiar, A Younis, I Hilldrup, MG Lucas Morriston Hospital, Swansea, United Kingdom Lidocaine/lignocaine gel is the standard agent used for intravesical local anaesthetic procedures. However gels may not provide an even mucosal coating and the physical characteristics of alkalinised lidocaine (AL) solution may result in more uniform spread and better absorption by bladder mucosa. Although AL can control pain in conditions like painful bladder/interstitial cystitis it has not been evaluated as a topical anaesthetic for intravesical procedures. We present a double-blind, parallel group, randomized controlled trial to compare the efficacy and morbidity of AL with lidocaine gel. Based on a power of 80% and alpha 0.05, 54 male and female patients (mean age 59.8 years) were randomly divided into 2 groups by centrally allocated, computer-generated random-number sequences. The primary outcome measure was average pain felt during the procedure assessed by visual analogue scale score. Results from http://www.selleck.cn/products/Cisplatin.html 50 patients showed a mean pain score of 14.41mm (AL) and 19.88mm (Gel), with no adverse events attributable to the anaesthetic agent in either group. Longer duration of contact appeared to increase efficacy. Graphical analysis showed a more even and predictable response in the AL group. These results provide level 1 evidence that both AL and lidocaine gel are equally effective and safe for topical intravesical anaesthesia prior to botulinum toxin injections, based on a significance level of 20mm mean difference in VAS. Increasing time between anaesthetic instillation and start of procedure is likely to increase efficacy. AL appears to provide a more uniform effect and therefore may be preferred.